9.4.3 Critically evaluates the safety and efficacy of traditional and pharmaceutical models as it applies to nutrition and dietetics
Ceci L, Han Y, Krutsinger K, Baiocchi L, Wu N, Kundu D, Kyritsi K, Zhou T, Gaudio E, Francis H, et al
Since 2021, semaglutide has also been approved specifically for chronic weight management in adults with a body mass index (BMI) of 27 or greater, those who have at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol
The gradual dose escalation schedule is specifically designed to minimise these moving up doses too quickly is the main reason gastrointestinal side effects become difficult to manage
However, like any medication combination, this approach should be carefully monitored by a healthcare provider to ensure its safe and effective